MedTrace Logo

Study to Investigate Effects of Antiischemic Drug Therapy in Silent Ischemia

NCT00382421 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2006-10-12

No results posted yet for this study

Summary

There is a lack of data on the prognostic importance of silent ischemia in totally asymptomatic subjects without history of coronary artery disease (CAD), and, particularly, on a possible benefit of medical therapy in such patients. SWISSI 1 therefore recruits totally asymptomatic subjects older than 40 years of age without any history of CAD but one cardiovascular risk factor with documented silent ischemia. Participants are randomized to open antianginal drug therapy and risk factor control versus only risk factor management and followed up for ≥ 10 years.

Conditions

  • Myocardial Ischemia

Interventions

DRUG

bisoprolol

DRUG

amlodipine

DRUG

molsidomine

DRUG

acetylsalicylic acid

Sponsors & Collaborators

  • Luzerner Kantonsspital

    lead OTHER

Principal Investigators

  • Paul Erne, MD · Department of Cardiology, Hospital Lucerne

  • Paul Erne, MD · Department of Cardiology, Hospital Lucerne

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1992-02-29
Completion
2006-04-30

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00382421 on ClinicalTrials.gov